Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer's Disease: Formulation Development and Optimization
Autor: | Giuseppina Raciti, Carmelo Puglia, Maria Grazia Sarpietro, Agata Campisi, Giovanni Sposito, Elisabetta Damiani, Edy Angela Siciliano, Annamaria Panico, Debora Santonocito |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Antioxidant
Oxygen radical absorbance capacity General Chemical Engineering medicine.medical_treatment SLN 02 engineering and technology Pharmacology medicine.disease_cause digestive system Article lcsh:Chemistry 03 medical and health sciences chemistry.chemical_compound Astaxanthin medicine General Materials Science MTT assay stealth system 030304 developmental biology 0303 health sciences Chemistry 021001 nanoscience & nanotechnology parenteral administration digestive system diseases Bioavailability astaxanthin lcsh:QD1-999 Systemic administration ORAC Nanocarriers 0210 nano-technology Alzheimer’s disease Oxidative stress |
Zdroj: | Nanomaterials Volume 11 Issue 2 Nanomaterials, Vol 11, Iss 391, p 391 (2021) |
Popis: | Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (< 200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |